DMEPOS Prior Authorization for Devices: Master, Required & the 2026 Exemption

A comprehensive guide to traditional Medicare DMEPOS prior authorization. Understand the Master and Required lists, the 2026 updates, and the 90% supplier exemption.

For manufacturers of Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS), the reimbursement pathway in traditional fee-for-service (FFS) Medicare is governed by strict compliance controls. While commercial plans and Medicare Advantage (MA) plans utilize individualized, often proprietary prior authorization policies (as detailed in our Medicare Advantage Prior Authorization Guide), traditional Medicare operates a centralized, code-specific prior authorization program.

Under this program, prior authorization is not merely an administrative hurdle—it is a mandatory condition of payment. If a DMEPOS item is subject to traditional Medicare prior authorization, the supplier must secure a "provisional affirmation" of coverage from their Durable Medical Equipment Medicare Administrative Contractor (DME MAC) before the item is delivered to the patient. If the supplier delivers the device without this affirmation, the claim will be denied automatically, and the supplier cannot bill the patient.

The landscape for DMEPOS prior authorization has undergone a major regulatory shift. With the finalization of the CY2026 Home Health Prospective Payment System and DMEPOS Final Rule (CMS-1828-F) and the subsequent Federal Register updates, CMS has introduced new product codes to the program and established a landmark supplier exemption process. In this detailed guide, we explain the mechanics of the Master and Required lists, analyze the 2026 code additions, unpack the new supplier exemption framework, and provide a strategic playbook for DME device manufacturers.

Scenario Question: Our company has developed a new active support surface, lower-limb prosthetic, or pneumatic compression device that has a valid HCPCS Level II code. Do our distributors and suppliers need to obtain Medicare prior authorization before delivering and billing our device, and how does the new 2026 supplier exemption affect our market access?

Direct Answer: Yes, if your device's HCPCS code is on the DMEPOS Required Prior Authorization List. That list — a small subset of the much larger DMEPOS Master List — holds 74 active codes as of April 13, 2026 (67 continuing, plus 7 added by the January 13, 2026 Federal Register update), spanning power mobility, lower-limb prosthetics, pressure-reducing support surfaces, spinal and knee orthoses, and, newly, pneumatic compression devices. Decisions now come within 5 business days (7 calendar days maximum), for both initial requests and resubmissions.

Since June 1, 2026, CMS has run a supplier exemption process under CMS-1828-F. Suppliers that submit at least 10 requests in the assessment window and hit a 90% provisional affirmation rate on initial requests — measured per PTAN and per DME MAC jurisdiction — are exempt from required prior authorization, subject to an annual post-payment review of a 10-claim sample that must again clear 90%. On CY2024 data, only about 6% of suppliers would have qualified. For manufacturers, the key levers are: (1) audit your HCPCS code status, (2) embed compliant clinical documentation templates in prescriber workflows, and (3) support your distributor channel's readiness both to qualify for the exemption and to survive the 10-claim review that keeps it.

1. What DMEPOS Prior Authorization Is and Why It Is a Condition of Payment

Traditional Medicare FFS historically operated on a retrospective billing model. A provider delivered a service or supplied a device, submitted a claim, and Medicare paid the claim based on established fee schedules. Post-payment audits (conducted by Recovery Audit Contractors or Unified Program Integrity Contractors) were used to claw back payments for claims that lacked medical necessity.

To curb high billing error rates and prevent fraudulent expenditures before they occurred, CMS established the DMEPOS prior authorization program under the authority of Section 1834(a)(15) of the Social Security Act. The program's initial implementation began on March 20, 2017, when CMS first required prior authorization for two power mobility device codes (K0856 and K0861) in four states, before expanding those codes nationwide later that year; pressure-reducing support surfaces were added to the Required List in a later phase (2019).

Under the current regulations codified at 42 CFR § 414.234, prior authorization is defined as a process through which a clinician or supplier submits documentation of medical necessity to the DME MAC for review prior to the item being furnished to the beneficiary.

Provisional Affirmation: The DME MAC reviews the clinical records and issues a "provisional affirmation" if the documentation demonstrates that the patient meets all Medicare coverage criteria (as defined by local coverage determinations and policy articles).
Condition of Payment: The provisional affirmation is a legal condition of payment. If a code is on the Required Prior Authorization List, Medicare will automatically reject any claim that does not reference a valid, active prior authorization tracking number.
Non-Affirmation Denials: If the DME MAC issues a "non-affirmation" (denial), the supplier can address the documentation gaps and resubmit the request. Under 42 CFR § 414.234(e)(4) there is no limit on the number of times a supplier can resubmit a prior authorization request. A non-affirmation decision is not itself appealable, because a prior authorization decision is not a payment determination (42 CFR § 405.926). Submitting the claim anyway and receiving the resulting denial, however, is an initial payment determination — and that denial carries the full five-level Medicare appeal rights. Suppliers who are confident in their documentation sometimes use this route deliberately to reach a Qualified Independent Contractor rather than loop through resubmissions.

For manufacturers, this means that if your product is on the Required List, your suppliers cannot and will not deliver it without first securing a provisional affirmation. Any friction in the prior authorization process directly translates into delivery delays, supplier cash-flow constraints, and reduced product sales.

2. The Master List vs the Required Prior Authorization List

The DMEPOS prior authorization program operates using two distinct lists compiled and updated by CMS:

A. The DMEPOS Master List

The Master List serves as the comprehensive registry of all DMEPOS items that are potentially subject to prior authorization. The inclusion criteria at 42 CFR § 414.234(b)(1) are more specific than most summaries suggest, and the precision matters if you are trying to predict whether a new HCPCS code will be captured. There are three independent doors onto the list:

Door 1 — Cost threshold plus a documented error/fraud finding. The item must be on the DMEPOS fee schedule and clear a payment threshold and appear in a qualifying report. The payment test is met if the item has an average purchase fee of $500 or more, or an average monthly rental fee schedule of $50 or more (both adjusted annually for inflation using CPI-U reduced by the 10-year moving average of multifactor productivity), or the item accounts for at least 1.5% of Medicare expenditures for all DMEPOS items over a 12-month period. On top of that, the item must be either (A) identified as having a high rate of potential fraud or unnecessary utilization in a nationally scoped OIG or GAO report published in 2015 or later, or (B) listed in a 2018-or-later CERT Medicare FFS Supplemental Improper Payment Data report as having a high improper payment rate.

Door 2 — Aberrant billing growth. Independently of the cost threshold, the annual Master List update captures any item with at least 1,000 claims and $1 million in payments during a recent 12-month period whose payment growth lacks an explanatory contributing factor (such as new technology or a coverage-policy change) and exceeds the greater of double the percent change of all qualifying DMEPOS claim payments from the preceding 12-month period, or a 30% increase in payment.

Door 3 — Statutory requirement. Any item that statutorily requires a face-to-face encounter, a written order prior to delivery, or prior authorization is on the list by operation of law.

Placement on the Master List does not mean prior authorization is required. The Master List is simply a pool of eligible codes; it is self-updating at least annually and published in the Federal Register. Removal follows four separate rules at § 414.234(b)(4)–(7), and the 10-year clock is not as clean as it is often described:

Items come off 10 years after being added — unless they were named in an OIG report, a GAO report, or a CERT high-improper-payment report within the 5-year period preceding the anticipated expiration date, which effectively restarts their exposure.
An item is removed at any time if its cost drops below the payment threshold.
Items that are discontinued or no longer covered by Medicare are removed.
An item is removed and replaced by its equivalent when its HCPCS code is discontinued and cross-walked.

There is no "fails the threshold for three consecutive years" test — a single drop below the threshold is sufficient grounds for removal, and conversely a fresh OIG, GAO, or CERT mention resets a code's practical shelf life.

B. The DMEPOS Required Prior Authorization List

The Required Prior Authorization List is a subset of the Master List. It contains the specific HCPCS codes for which prior authorization is a mandatory condition of payment.

CMS selects codes from the Master List and moves them to the Required List through a Federal Register notice, typically providing at least 60 days of advance notice before prior authorization requirements become effective. CMS manages the size of the Required List based on DME MAC administrative capacity and the program's target expenditures.

       DMEPOS Prior Authorization Code Pipeline
+------------------------------------------------------+
|             DMEPOS Fee Schedule Codes                |
+--------------------------+---------------------------+
                           |
                           v ($500+ buy / $50+ rent / 1.5% of spend
                           |  + OIG/GAO/CERT finding, OR aberrant
                           |  billing growth, OR statutory mandate)
+------------------------------------------------------+
|             DMEPOS Master List                       |
|   - Potentially subject to PA                        |
|   - 10 years, reset by new OIG/GAO/CERT findings     |
+--------------------------+---------------------------+
                           |
                           v (Selected by CMS for active enforcement)
+------------------------------------------------------+
|       DMEPOS Required Prior Authorization List       |
|   - Active condition of payment                      |
|   - Requires DME MAC provisional affirmation          |
+------------------------------------------------------+

3. Which Device Categories Are Exposed to DMEPOS PA

The Required Prior Authorization List is concentrated in five major medical device and supplier categories:

A. Power Mobility Devices (PMDs)

PMDs are by far the largest block on the Required List — roughly 46 of the 74 active codes. CMS built this category in four waves: K0856 and K0861 (March 20, 2017, initially in Illinois, Missouri, New York, and West Virginia, then nationwide July 17, 2017); 31 additional PMD codes on September 1, 2018; seven more (K0857–K0860, K0862–K0864) on July 22, 2019; and six power-operated vehicle and Group 1/2 codes (K0800, K0801, K0802, K0806, K0807, K0808) on April 13, 2022. These codes require extensive documentation, including a face-to-face mobility evaluation by the prescribing physician and a specialty evaluation by a licensed physical or occupational therapist. Separately, CMS maintains a voluntary prior authorization list of 53 PMD accessories that suppliers may submit alongside a PMD base request.

B. Lower-Limb Prosthetics (LLPs)

Advanced prosthetic components, particularly microprocessor-controlled knees (HCPCS code L5856, L5857, L5858), microprocessor-controlled ankles (L5973), and high-activity feet, require prior authorization. The clinical review focuses on verifying the patient's functional K-level (specifically K3 or K4), which represents their potential to navigate environmental barriers.

C. Pressure-Reducing Support Surfaces (PRSS)

Exactly five PRSS codes are on the Required List: powered air flotation beds / low air loss therapy (E0193), powered pressure-reducing air mattresses (E0277), non-powered advanced pressure-reducing overlays (E0371), powered air overlays (E0372), and non-powered advanced pressure-reducing mattresses (E0373). They were phased in from July 22, 2019 (California, Indiana, New Jersey, North Carolina) and went nationwide on October 21, 2019. Reviewers require documentation of the qualifying pressure-injury stage, failure of prior conservative wound care, and a comprehensive care plan. Note a common misconception: air-fluidized beds (E0194) are Group 3 support surfaces but are not on the Required Prior Authorization List — they are managed through ordinary medical review, not as a condition of payment.

D. Spinal and Knee Orthoses

This is the fastest-growing category, added in three tranches to target the high error rates associated with telemarketing-driven supplier schemes. The 2022 tranche covered lumbo-sacral and knee orthoses (L0648, L0650, L1832, L1851 — plus L1833, which was later removed from both lists effective August 12, 2024). Six more codes (L0631, L0637, L0639, L1843, L1845, L1951) went nationwide on August 12, 2024, and five more (L0651, L1844, L1846, L1852, L1932) on April 13, 2026. CMS has also suspended prior authorization for L0648, L0650, L1832, L1833, and L1851 in narrow urgent or special-circumstance situations where even the two-business-day expedited review would risk the beneficiary's health.

E. Pneumatic Compression Devices (PCDs)

Pneumatic compression pumps E0651 (segmental, without calibrated gradient pressure) and E0652 (segmental, with calibrated gradient pressure), used for lymphedema or chronic venous insufficiency, became subject to prior authorization nationwide on April 13, 2026 — the newest category in the program. Reviewers require proof of conservative therapy failure (such as compression stockings and elevation) over a multi-month period. Manufacturers in this space had no prior-authorization exposure at all before April 2026, which makes it the category where distributor readiness is weakest.

4. The 2026 Updates: New Master and Required List Additions

Under the Federal Register update published on January 13, 2026:

Master List Expansion: CMS added 18 new HCPCS codes to the DMEPOS Master List, effective April 13, 2026.
Required List Expansion: CMS selected 7 HCPCS codes from the Master List for the Required Prior Authorization List — five orthoses (L0651, L1844, L1846, L1852, L1932) and two pneumatic compression devices (E0651, E0652).
Effective Date: Prior authorization became an active condition of payment for these seven codes nationwide on April 13, 2026. Suppliers who delivered these items to Medicare beneficiaries on or after that date without a provisional affirmation face immediate claim rejections.
Resulting List Size: The same notice states that the program for the 67 HCPCS codes already subject to prior authorization continues uninterrupted, putting the Required List at 74 active codes after the April 2026 additions.

One category is worth flagging because it is easy to misread: three osteogenesis stimulator codes (E0747, E0748, E0760) were added to the Required List on August 12, 2024, but CMS suspended the requirement for them just over two weeks later, on August 28, 2024, pending further rulemaking on the three-year expected-life requirement at 42 CFR § 414.202. CMS can suspend prior authorization for any item at any time without rulemaking under § 414.234(f), so a code appearing on a published list is not by itself proof that the requirement is currently being enforced — check the CMS program page's suspension notices before advising a distributor.

Manufacturers of products falling under the new codes should immediately update their customer-facing billing guides and verify that their clinical support materials align with the DME MAC local coverage requirements. For products that also carry outpatient or physician-office billing paths, cross-check the code assignments in our CPT, HCPCS, and ICD coding strategy guide for device reimbursement before rewriting supplier collateral.

5. The New Supplier Exemption Process (CMS-1828-F)

While the expansion of the Required List increases the administrative burden on suppliers, CMS has finalized a major operational relief mechanism. The CY 2026 Home Health Prospective Payment System and DMEPOS Final Rule (CMS-1828-F) — issued November 28, 2025 and published in the Federal Register on December 2, 2025 (90 FR 55342) — added operational specificity to the supplier exemption authority that already sat at 42 CFR § 414.234(c)(1)(ii) ("CMS may elect to exempt suppliers from prior authorization upon demonstration of compliance with Medicare coverage, coding, and payment rules through such prior authorization process").

This exemption program is modeled on the hospital outpatient department prior authorization exemption at 42 CFR § 419.83(c). The framework operates as follows:

A. The 90% Affirmation Threshold

To qualify for an exemption, a DMEPOS supplier must demonstrate high clinical documentation compliance. Specifically, the supplier must submit at least 10 prior authorization requests during the assessment window and achieve a provisional affirmation rate of 90% or higher on initial requests.

The DME MACs calculate this rate from initial (not resubmitted) prior authorization requests, which is the detail most suppliers miss — a package that is non-affirmed and then affirmed on resubmission still counts against the rate.
Eligibility is assessed per PTAN and per DME MAC jurisdiction, not per corporate entity. A multi-location supplier can be exempt in one jurisdiction and not another, which matters for any manufacturer modeling national channel coverage.
For the first cycle, the assessment window ran June 1 – November 30, 2025.
In the final rule's own analysis of CY2024 data, only about 6% of suppliers would have met the 90% threshold, indicating that qualifying requires a highly disciplined clinical intake process.

B. The Exemption Timeline and Notification

The first exemption cycle began on June 1, 2026:

Supplier Notification: DME MACs evaluated supplier performance and issued formal notices of exemption status no later than April 2, 2026.
Opt-Out Period: Opting out is permitted — some suppliers prefer the administrative certainty of a pre-delivery review over post-payment audit risk, and CMS agreed in the final rule to preserve voluntary participation. The standing deadline is April 30 in the year preceding each annual cycle. For the first cycle only, CMS extended the window: under its May 18, 2026 update, suppliers had through May 26, 2026 to opt out, after which opt-out requests were denied.
Exemption Window: For suppliers that did not opt out, the exemption began June 1, 2026 and runs on an annual cycle thereafter. Formally the exemption "remains in effect until CMS elects to withdraw" it, with eligibility reassessed each cycle — so treat it as an annually re-earned status, not a fixed one-year grant. Prior authorization requests received from an exempt supplier during the exemption period are rejected.

C. Annual Post-Payment Medical Review

The exemption is not a blank check. To protect the Medicare Trust Fund, exempt suppliers are subject to an annual post-payment audit:

The DME MAC selects a 10-claim sample with dates of service inside the exemption period. To stay eligible, the supplier must have billed at least 10 claims during that period.
The review is triggered by an Additional Documentation Request (ADR) issued on January 1. The supplier has 45 days to respond; failure to respond results in claim denial — which then counts as a failure in the sample.
Exemption Renewal: If the compliance rate on the sample is 90% or greater, the exemption continues. Continuation or removal notices are mailed no later than April 2.
Exemption Withdrawal: If the rate of non-payable claims exceeds 10%, the exemption is withdrawn and the supplier returns to standard prior authorization. CMS must provide at least 60 days' notice before an exemption starts or is withdrawn.

The 10-claim sample deserves a hard look from anyone building channel strategy around this program. With a sample of exactly 10, the 90% threshold means a single failed claim is the maximum tolerance — two failures ends the exemption. That is a far less forgiving standard than the qualifying phase, where a supplier submitting 200 requests can absorb 20 non-affirmations. A distributor that squeaks into the exemption at 90–92% on volume is statistically likely to lose it at the first post-payment review, and will then be re-entering standard prior authorization with no pre-built submission workflow. For manufacturers, that is the failure case to design against: not the supplier who never qualifies, but the supplier who qualifies, dismantles its prior authorization function, and loses the exemption twelve months later.

D. Administrative and Financial Impact

In the final rule's regulatory impact analysis, CMS estimated the total DME MAC prior authorization workload at $13,194,555 annually (based on CY2024 volumes). The agency projected a ~17% workload reduction (representing $2,243,074 in administrative savings for the Medicare program) once the exemption process is fully implemented, driven by the reduction in standard prior authorization reviews. For suppliers, the financial benefit is significant: qualifying for the exemption eliminates pre-delivery administrative delays, allowing them to deliver devices immediately and improve cash flow.

6. Provisional Affirmation, Denials, and Audits: The Operational Workflow

For suppliers who do not qualify for the exemption (or who choose to opt out), navigating the standard DMEPOS prior authorization workflow requires a precise operational cadence.

                  Standard DMEPOS Prior Authorization Workflow
                                     |
    +--------------------------------+--------------------------------+
    |                                                                 |
1. Physician Order & Documentation                              2. Intake & Audit
  - Face-to-Face evaluation note                                  - Supplier reviews EHR records
  - Detailed written order (SWO)                                  - Verifies criteria alignment
                                                                      |
                                                                      v
                                                              3. Submit to DME MAC
                                                                  - Standard: 5 business days
                                                                    (max 7 calendar days)
                                                                  - Expedited: 2 business days
                                                                      |
                                    +---------------------------------+---------------------------------+
                                    |                                                                   |
                            [Provisional Affirmation]                                          [Non-Affirmation]
                                    |                                                                   |
                            4. Deliver & Bill                                                   4. Rectify Gaps
                                - Reference UTN on claim                                            - Resubmit with updates
                                - Protected from standard audits                                    - Unlimited resubmissions

A. Submission and Review Timelines

The supplier submits the prior authorization request to the DME MAC via the CMS Enterprise Portal (esMD), the MAC's supplier portal, fax, or mail. The review timelines were materially shortened in the last two years, and stale guidance is still circulating:

Standard Decisions: The DME MAC sends a decision letter within 5 business days, not to exceed 7 calendar days, of receiving the request. This reflects a CMS change effective January 1, 2025 that cut the standard review window to no more than 7 calendar days. Any supplier playbook still citing the original 10 business day standard is out of date.
Resubmissions: Resubmitted requests are now held to the same 5 business days / 7 calendar days clock. This is the larger practical improvement — resubmissions previously carried a 20 business day timeline, meaning a single non-affirmation could add a month to delivery. Under the current standard, a non-affirmation plus a corrected resubmission costs roughly two weeks rather than six.
Expedited Decisions: If the supplier demonstrates that the standard timeline could seriously jeopardize the patient's life, health, or ability to regain maximum function, the DME MAC makes reasonable efforts to decide within 2 business days. Expedited requests should go by fax, esMD, or portal, never mail.

The convergence here is worth noting for anyone selling into both channels: as of January 1, 2026, traditional Medicare DMEPOS prior authorization (7 calendar days maximum) and Medicare Advantage standard prior authorization (7 calendar days) run to the same outer bound — traditional Medicare simply got there a year earlier.

B. The Unique Tracking Number (UTN)

When the DME MAC issues a provisional affirmation, it assigns a Unique Tracking Number (UTN) to the approval.

The supplier must place this UTN on the final claim (CMS-1500 or electronic equivalent) when billing Medicare.
Audit Protection — and its two express limits: A provisional affirmation gives real protection against a later medical-necessity reversal, but it is not absolute. Under 42 CFR § 414.234(c)(2)(ii), a claim that received a provisional affirmation may still be denied for (A) technical requirements that can only be evaluated once the claim is formally processed, and (B) information that was not available at the time of the prior authorization request. In practice that means eligibility, coding, supplier-enrollment, and date-of-service problems remain live risks even with a valid UTN — the affirmation buys you medical necessity, not claim correctness.

C. The Cost of Getting It Wrong

If a supplier delivers an item without obtaining prior authorization (or after receiving a non-affirmation), the consequences are serious but frequently overstated:

Claims for codes subject to required prior authorization that are submitted without a corresponding UTN are automatically denied.
Beneficiary liability is not automatically foreclosed. This is the point most supplier guidance gets wrong. Under section 13.1 of the CMS DMEPOS Prior Authorization Operational Guide, if a claim is submitted without a prior authorization decision and is flagged as having an Advance Beneficiary Notice of Noncoverage (ABN) — billed with the GA modifier — the contractor stops the claim, requests documentation, and reviews the ABN's validity under standard ABN policy (Medicare Claims Processing Manual, Pub. 100-04, Chapter 30, § 40). A validly executed ABN can therefore still shift financial liability to the beneficiary.
What suppliers cannot do is treat an ABN as a substitute for the prior authorization process, or execute one routinely or retroactively. A boilerplate ABN issued to every patient will fail the standard validity test, and the claim becomes a supplier write-off.
Because a non-affirmation itself is not appealable, the denied claim — not the non-affirmation — is the document that opens the appeal path.

7. A Device Manufacturer's Playbook for DMEPOS PA-Exposed Products

For medical device manufacturers, the DMEPOS prior authorization program represents a major channel risk. If your distributors and suppliers are struggling to secure approvals, they will actively divert patients to alternative, non-PA-managed products. That substitution pressure is the mechanism behind several category shifts already visible in the market — the move toward disposable wound-therapy platforms analysed in our single-use NPWT devices FDA and CMS coding guide is a clear example of billing-pathway friction reshaping product design. To mitigate this risk, manufacturers should implement the following strategic playbook:

Step 1: Standardize Clinical Documentation Kits

Create highly structured "clinical documentation kits" for prescribing physicians:

Provide clear guidelines on what details must be documented in the physician's face-to-face clinical notes (e.g., specific joint measurements for prosthetics, wound measurements for support surfaces, or conservative therapy timelines for pneumatic compression).
Provide template Standard Written Orders (SWO) that contain all CMS-required elements (beneficiary name, order date, detailed description of the item, physician signature).
Ensure these kits do not use leading language or pre-completed clinical check-boxes, as DME MACs reject templated forms that do not reflect independent clinical judgment.

Step 2: Establish a Supplier Exemption Support Program

Because the 2026 supplier exemption provides a major competitive advantage, help your primary distributor network achieve and maintain the 90% affirmation threshold:

Audit a sample of your distributors' prior authorization submissions to identify common denial root causes (e.g., missing physician signatures, outdated clinical evaluations).
Provide training for supplier intake teams on how to navigate the esMD system and structure their clinical packages.
For suppliers approaching the 90% threshold, deploy clinical coordinators to help resolve document gaps before submission, accelerating their qualification for the June 1 exemption cycle.

Step 3: Implement Post-Payment Audit Readiness Systems

For suppliers operating under the 2026 exemption, the primary risk shifts from pre-delivery prior authorization to the annual post-payment review:

Since a failure rate of more than 10% during the annual review (minimum 10-claim sample) will result in the immediate withdrawal of the exemption, manufacturers must ensure their suppliers maintain airtight records.
Conduct proactive mock audits on your suppliers' active Medicare accounts.
Verify that the clinical records supporting every delivered device are complete, signed, and archived, ensuring the supplier can survive the annual post-payment check.

Step 4: Contrast MA and FFS Workflows in GTM Strategy

Ensure your sales team can guide providers through the different rules:

For FFS Medicare patients, emphasize that prior authorization is code-specific and mandatory before delivery.
For Medicare Advantage patients, guide providers to check individual plan policies, which may require prior authorization for codes that are exempt under FFS Medicare — and note that the FFS supplier exemption has no MA equivalent, so an exempt supplier still faces full prior authorization on its MA volume.
Cross-reference our Medicare Advantage prior authorization guide for medical devices to help customers navigate plan-level variation.
Situate both channels inside the wider payment picture using our complete medical device reimbursement guide, and for connected-device portfolios that straddle DME and physician-billed monitoring, our remote patient monitoring device pathway and CMS reimbursement guide.

8. Frequently Asked Questions

What is the difference between the DMEPOS Master List and the Required Prior Authorization List?

The Master List is a self-updating compilation of DMEPOS codes that meet the criteria at 42 CFR § 414.234(b)(1) — an average purchase fee of $500 or more, an average monthly rental fee schedule of $50 or more, or at least 1.5% of all Medicare DMEPOS expenditures, combined with an adverse OIG, GAO, or CERT finding; or, separately, aberrant billing growth; or a statutory mandate. The Required Prior Authorization List is a much smaller subset selected by CMS from the Master List for active enforcement — 74 codes as of April 2026. Prior authorization is only a mandatory condition of payment for codes on the Required List.

How many DMEPOS codes currently require prior authorization?

74, as of the April 13, 2026 effective date: the 67 codes CMS described as continuing uninterrupted in its January 13, 2026 Federal Register notice, plus the seven newly selected codes (orthoses L0651, L1844, L1846, L1852, L1932 and pneumatic compression devices E0651, E0652). Three osteogenesis stimulator codes (E0747, E0748, E0760) sit on the list but have been suspended since August 28, 2024, so they are not currently enforced.

Which DMEPOS device categories require Medicare prior authorization as a condition of payment?

The program currently targets five primary categories: power mobility devices (Group 3 power wheelchairs), lower-limb prosthetics (microprocessor-controlled knees and ankles), pressure-reducing support surfaces (the five Group 2 mattresses and overlays E0193, E0277, E0371, E0372, and E0373 — note that air-fluidized beds (E0194) are not on the Required List), certain off-the-shelf and custom-fitted spinal and knee orthoses, and pneumatic compression devices.

How does the new 2026 DMEPOS prior authorization exemption work, and who qualifies?

Under CMS-1828-F, DMEPOS suppliers that submit at least 10 prior authorization requests in the assessment window and achieve a provisional affirmation rate of 90% or higher on initial requests can be exempt from required prior authorization. Eligibility is calculated separately for each PTAN and DME MAC jurisdiction. Exempt suppliers deliver devices immediately without submitting pre-delivery requests, and any requests they do submit are rejected. To maintain the exemption, the supplier must bill at least 10 claims during the exemption period and pass a post-payment review of a 10-claim sample at a 90% or higher compliance rate. Only about 6% of suppliers would have met the threshold on CY2024 data.

When does the first DMEPOS prior authorization exemption cycle begin, and how do suppliers opt out?

The first cycle began on June 1, 2026, based on a June 1 – November 30, 2025 assessment window. DME MACs issued eligibility notices no later than April 2, 2026. The standing opt-out deadline is April 30 before each annual cycle; for the first cycle only, CMS extended it through May 26, 2026. Requests received after that date were denied.

How long does a DMEPOS prior authorization decision take?

The DME MAC issues a decision within 5 business days, not to exceed 7 calendar days, for both initial requests and resubmissions — a standard that took effect January 1, 2025 and replaced the prior 10-business-day (initial) and 20-business-day (resubmission) timelines. Expedited requests, where the standard timeline would seriously jeopardize the beneficiary's life, health, or ability to regain maximum function, are decided within 2 business days.

What happens if a supplier delivers a DMEPOS item without obtaining prior authorization when required?

The claim is automatically denied for lack of a Unique Tracking Number. Contrary to a common belief, this does not automatically make the item a supplier write-off: if the supplier obtained a valid Advance Beneficiary Notice of Noncoverage and bills with the GA modifier, the contractor stops the claim and reviews the ABN's validity under standard ABN policy (Pub. 100-04, Chapter 30, § 40), and a valid ABN can shift liability to the beneficiary. A routine, boilerplate, or retroactive ABN will not survive that validity test, and the supplier absorbs the cost. An ABN is never a substitute for submitting the prior authorization request.